Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03635659 in moderate COPD
NCT01033487Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2010
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-03635659 in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Pfizer. Primary endpoints: Change From Baseline in Trough Forced Expiratory Volume in 1 Second at 24.5 hours, Maximum Observed Plasma Concentration up to 48 hours and 3 more. Started Jan 2010; status: completed.
02
Drugs
PF-03635659
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01033487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01033487.